Headquartered in Paris, Inato helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials by discovering untapped research site potential. Recently, the company has raised €13 million in a Series A round of venture capital financing.
The company will use the funding to expand its predictive capabilities to match the right sites with the right studies and develop a comprehensive network of clinicians worldwide.